Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO). A Meet-URO Group Real World Study (Meet-Uro 7) - Meet-URO

Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO). A Meet-URO Group Real World Study (Meet-Uro 7)

Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO). A Meet-URO Group Real World Study (Meet-Uro 7)

Autore

Daniele Santini, Marco Stellato

Patologia

Rene

Rivista

American Journal Of Clinical Oncology

Anno

2021

DOI

https://doi.org/10.1097/coc.0000000000000791

Studio di riferimento